Association of endostatin with mortality in patients with chronic heart failure

BackgroundExperimental data imply that in decompensated heart failure (HF), the anti-angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all-cause mortality in a prospective cohort study of chronic HF patients. MethodsIn this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow-up of 31months. ResultsOne fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations >245ng/mL were associated with higher risk of all-cause mortality [HR 87 (95% CI 25-300); P=0001] in the multivariate analysis as compared to endostatin concentrations 245ng/mL. When both endostatin and NT-proBNP were above the calculated cut-off of 245ng/mL and 2386pg/mL, respectively, the prognostic utility of both biomarkers increased [HR 408 (95% CI 47-3546); P=0001] compared with values lower than the cut-offs. ConclusionsSerum endostatin concentrations are independently associated with all-cause mortality. Furthermore, combination of endostatin and NT-proBNP discriminates patients at high risk.